Heather Bristol’s Post

In this video series with Applied Clinical Trials Magazine editor Andy Studna, Parexel's Mwango Kashoki shares her reaction to the FDA's new guidance on conducting multiregional clinical trials in oncology. The guidance requires companies to proactively plan trials to ensure data applicability to the US population ─ considering factors like patient characteristics ─ to improve patient access and ensure broader representation. Did you read the FDA's guidance? Let me know what you think! #regulatory #oncology #clinicaltrials #fda

In this video series with Applied Clinical Trials Magazine editor Andy Studna, Parexel's Mwango Kashoki shares her reaction to the FDA's new guidance on conducting multiregional clinical trials in oncology. The guidance requires companies to proactively plan trials to ensure data applicability to the US population ─ considering factors like patient characteristics ─ to improve patient access and ensure broader representation. Did you read the FDA's guidance? Let me know what you think! #regulatory #oncology #clinicaltrials #fda

In this video series with Applied Clinical Trials Magazine editor Andy Studna, Parexel's Mwango Kashoki shares her reaction to the FDA's new guidance on conducting multiregional clinical trials in oncology. The guidance requires companies to proactively plan trials to ensure data applicability to the US population ─ considering factors like patient characteristics ─ to improve patient access and ensure broader representation. Did you read the FDA's guidance? Let me know what you think! #regulatory #oncology #clinicaltrials #fda

In this video series with Applied Clinical Trials Magazine editor Andy Studna, Parexel's Mwango Kashoki shares her reaction to the FDA's new guidance on conducting multiregional clinical trials in oncology. The guidance requires companies to proactively plan trials to ensure data applicability to the US population ─ considering factors like patient characteristics ─ to improve patient access and ensure broader representation. Did you read the FDA's guidance? Let us know what you think! #regulatory #oncology #clinicaltrials #fda

In this video series with Applied Clinical Trials Magazine editor Andy Studna, Parexel's Mwango Kashoki shares her reaction to the FDA's new guidance on conducting multiregional clinical trials in oncology. The guidance requires companies to proactively plan trials to ensure data applicability to the US population ─ considering factors like patient characteristics ─ to improve patient access and ensure broader representation. Did you read the FDA's guidance? Let me know what you think! #regulatory #oncology #clinicaltrials #fda

In this video series with Applied Clinical Trials Magazine editor Andy Studna, Parexel's Mwango Kashoki shares her reaction to the FDA's new guidance on conducting multiregional clinical trials in oncology. The guidance requires companies to proactively plan trials to ensure data applicability to the US population ─ considering factors like patient characteristics ─ to improve patient access and ensure broader representation. Did you read the FDA's guidance? Let me know what you think! #regulatory #oncology #clinicaltrials #fda

In this video series with Applied Clinical Trials Magazine editor Andy Studna, Parexel's Mwango Kashoki shares her reaction to the FDA's new guidance on conducting multiregional clinical trials in oncology. The guidance requires companies to proactively plan trials to ensure data applicability to the US population ─ considering factors like patient characteristics ─ to improve patient access and ensure broader representation. Did you read the FDA's guidance? Let me know what you think! #regulatory #oncology #clinicaltrials #fda

In this video series with Applied Clinical Trials Magazine editor Andy Studna, Parexel's Mwango Kashoki shares her reaction to the FDA's new guidance on conducting multiregional clinical trials in oncology. The guidance requires companies to proactively plan trials to ensure data applicability to the US population ─ considering factors like patient characteristics ─ to improve patient access and ensure broader representation. Did you read the FDA's guidance? Let me know what you think! #regulatory #oncology #clinicaltrials #fda

In this video series with Applied Clinical Trials Magazine editor Andy Studna, Parexel's Mwango Kashoki shares her reaction to the FDA's new guidance on conducting multiregional clinical trials in oncology. The guidance requires companies to proactively plan trials to ensure data applicability to the US population ─ considering factors like patient characteristics ─ to improve patient access and ensure broader representation. Did you read the FDA's guidance? Let me know what you think! #regulatory #oncology #clinicaltrials #fda

In this video series with Applied Clinical Trials Magazine editor Andy Studna, Parexel's Mwango Kashoki shares her reaction to the FDA's new guidance on conducting multiregional clinical trials in oncology. The guidance requires companies to proactively plan trials to ensure data applicability to the US population ─ considering factors like patient characteristics ─ to improve patient access and ensure broader representation. Did you read the FDA's guidance? Let me know what you think! #regulatory #oncology #clinicaltrials #fda